stocks logo

ELTX

Elicio Therapeutics Inc
$
9.650
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
9.650
Open
9.650
VWAP
9.65
Vol
8.12K
Mkt Cap
157.66M
Low
9.650
Amount
78.34K
EV/EBITDA(TTM)
--
Total Shares
10.27M
EV
144.91M
EV/OCF(TTM)
--
P/S(TTM)
--
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-0.480
-65.47%
--
--
-0.350
-65.69%
--
--
-0.610
-29.89%
Estimates Revision
The market is revising No Change the revenue expectations for Elicio Therapeutics, Inc. (ELTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 78.37%.
EPS Estimates for FY2025
Revise Downward
down Image
-20.22%
In Past 3 Month
Stock Price
Go Up
up Image
+78.37%
In Past 3 Month
3 Analyst Rating
up Image
29.53% Upside
Wall Street analysts forecast ELTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELTX is 12.50 USD with a low forecast of 12.00 USD and a high forecast of 13.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
up Image
29.53% Upside
Current: 9.650
sliders
Low
12.00
Averages
12.50
High
13.00
H.C. Wainwright
Buy
maintain
$10 -> $13
2025-07-17
Reason
H.C. Wainwright raised the firm's price target on Elicio Therapeutics to $13 from $10 and keeps a Buy rating on the shares. The firm says investor focus is on the interim analysis from the randomized Phase 2 portion of the AMPLIFY-7P trial in Q3.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$10
2025-04-02
Reason
Jones Trading
Soumit Roy
Strong Buy
Initiates
$9
2024-10-31
Reason
JonesResearch analyst Soumit Roy initiated coverage of Elicio Therapeutics with a Buy rating and $9 price target. Elicio's off-the-shelf cancer vaccine candidate is "probably given the best possible chance to succeed," the analyst tells investors in a research note. The firm says the company's AMP platform delivers neoantigen peptides to the lymph nodes to generate better immune response, a hot tumor type in post-surgical setting but with biomarker positive status.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$10
2024-08-23
Reason

Valuation Metrics

The current forward P/E ratio for Elicio Therapeutics Inc (ELTX.O) is -4.50, compared to its 5-year average forward P/E of -2.31. For a more detailed relative valuation and DCF analysis to assess Elicio Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.31
Current PE
-4.50
Overvalued PE
-1.32
Undervalued PE
-3.30

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
-7.63%
-10.09M
Operating Profit
FY2025Q2
YoY :
+46.09%
-10.56M
Net Income after Tax
FY2025Q2
YoY :
+3.13%
-0.66
EPS - Diluted
FY2025Q2
YoY :
-0.22%
-8.95M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ELTX News & Events

Events Timeline

2025-08-12 (ET)
2025-08-12
08:13:38
Elicio announces publication of ELI-002 updated AMPLIFY-201 Phase 1 data
select
2025-08-05 (ET)
2025-08-05
07:29:04
Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2
select
2025-06-04 (ET)
2025-06-04
08:03:46
Elicio Therapeutics secures $10M in financing
select
Sign Up For More Events

News

4.0
07-17Benzinga
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $13
1.0
06-17Newsfilter
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
8.5
06-04Newsfilter
Elicio Therapeutics Secures $10 Million in Financing
Sign Up For More News

FAQ

arrow icon

What is Elicio Therapeutics Inc (ELTX) stock price today?

The current price of ELTX is 9.65 USD — it has increased 0 % in the last trading day.

arrow icon

What is Elicio Therapeutics Inc (ELTX)'s business?

arrow icon

What is the price predicton of ELTX Stock?

arrow icon

What is Elicio Therapeutics Inc (ELTX)'s revenue for the last quarter?

arrow icon

What is Elicio Therapeutics Inc (ELTX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Elicio Therapeutics Inc (ELTX)'s fundamentals?

arrow icon

How many employees does Elicio Therapeutics Inc (ELTX). have?

arrow icon

What is Elicio Therapeutics Inc (ELTX) market cap?